6-bromo-3-(4-methoxyphenyl)imidazo[1,2-a]pyridine | 474706-75-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-bromo-3-(4-methoxyphenyl)imidazo[1,2-a]pyridine
• CAS: 474706-75-7
• 化学式: C₁₄H₁₁BrN₂O
• 分子量: 303.158
• InChiKey: QYXUHNJFCDLQRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 6-bromo-3-(4-methoxyphenyl)imidazo[1,2-a]pyridine 、 1-(4-fluorophenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 生成 6-[2-(4-fluorophenyl)-2H-pyrazol-3-yl]-3-(4-methoxyphenyl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Imidazopyridine derivatives

  摘要：

  本发明涉及通式化合物，其中Ar为苯基或吡啶基；X1为N或CH，X2为N或CH，但仅有X1或X2为N，另一个为CH；R1为氢、卤素、较低烷基、较低烷氧基、被卤素、氰或S（O）2-较低烷基取代的较低烷基；R2为氢、卤素、较低烷基、较低烷氧基、被卤素或氰取代的较低烷基；n为1或2；或其药学上可接受的酸盐、外消旋体混合物或其对应的对映异构体。该化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩性脊髓侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、神经活性药物滥用，如酒精、阿片类、甲基苯丙胺、苯环已呋喃和可卡因。

  公开号：

  US09315502B2
• 作为产物：
  描述：

  6-溴-3-碘咪唑并[1,2-A]吡啶 、 4-甲氧基苯硼酸 在 四(三苯基膦)钯 1,3-丙二醇 、 potassium phosphate 作用下， 以 乙醚 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 4.0h， 生成 6-bromo-3-(4-methoxyphenyl)imidazo[1,2-a]pyridine
  参考文献：
  名称：

  NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

  摘要：

  公开号：

  EP1382603B1

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014082979A1

  公开（公告）日：2014-06-05

  The present invention relates to compounds of general formula (I) wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(O)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及通式（I）的化合物，其中Ar是苯基或吡啶基；X1是N或CH，X2是N或CH，但只有X1或X2是N，而另一个是CH；R1是氢，卤素，低烷基，低烷氧基，低烷基被卤素，氰或S（O）2-低烷基取代的；R2是氢，卤素，低烷基，低烷氧基，低烷基被卤素或氰取代的；n为1或2；或其药学上可接受的酸加合物，外消旋混合物或其对应的对映体和/或光学异构体。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、神经活性药物滥用，如酒精、鸦片类、甲基苯丙胺、苯环利定和可卡因。
• IMIDAZOPYRIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150259341A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X 1 is N or CH, X 2 is N or CH, with the proviso that only one of X 1 or X 2 is N and the other is CH; R 1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(0) 2 -lower alkyl; R 2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及通式化合物，其中Ar为苯基或吡啶基; X1为N或CH，X2为N或CH，但只有X1或X2是N，另一个是CH; R1为氢、卤素、低碳基、低烷氧基、低碳基取代的卤素、氰或S（0）2-低碳基; R2为氢、卤素、低碳基、低烷氧基、低碳基取代的卤素或氰; n为1或2; 或其药学上可接受的酸加盐、外消旋混合物或其相应的对映体和/或光学异构体。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、神经活性药物滥用，如酒精、阿片类、甲基苯丙胺、苯环利定和可卡因。
• Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
  申请人：Eisai Co., Ltd.

  公开号：US07074801B1

  公开（公告）日：2006-07-11

  The present invention discloses compounds and compositions of formula (I): having inhibitory activity on activation of STAT6, wherein X represents quinoline, isoquinoline, quinazoline or imidazopyridine; Y represents phenyl, piperazine, pyridine, thiophene, thiazole, oxathiazole or oxathiadiazole; and variables Z, n, R1, R2, R3 and R4 are as defined in the claims.

  本发明揭示了具有抑制STAT6激活活性的式（I）的化合物和组合物，其中X代表喹啉，异喹啉，喹唑啉或咪唑吡啶; Y代表苯基，哌嗪基，吡啶基，噻吩基，噻唑基，氧硫噻唑基或氧硫氮杂二唑基; 变量Z，n，R1，R2，R3和R4如权利要求所定义。
• NITROGENOUS FUSED&minus;RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1382603A1

  公开（公告）日：2004-01-21

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，X代表含氮缩合芳香杂环基团，如咪唑并[1,2-a]吡啶、苯并咪唑、喹唑啉、喹啉或2,1-苯并异噁唑，并有(R4)n作为取代基；Y代表C3-8环烷基、C4-8环烯基、5～14元非芳香杂环基团、C6-14芳香烃环基或5～14元芳香杂环基团；(R4)n 中的 n 是 0、1、2 或 3，Z 基团独立地代表：(1) 氢原子，(2) 氨基，(3) 卤素原子，(4) 羟基，(5) 硝基，(6) 氰基，(7) 叠氮基，(8) 甲酰基，(9) 羟基氨基、(10) 氨基磺酰基，(11) 氨基胍基，(12) 氧代基，(13) C2-6 烯基，(14) C1-6 烷氧基，(15) C1-6 烷基羟基氨基，(16) 卤代 C1-6 烷基，(17) 卤代 C2-6 烯基，(18) (i) C3-7 环烷基、(ii) C3-7 环烯基，(iii) 5-14 元非芳杂环基团，其中每个基团可有一个或多个取代基 Q，或 (19) 式-M1-M2-M3，R1 代表 (1) 氢原子，(2) 卤素原子，(3) 羟基、(4) 硝基，(5) 氰基，(6) 卤代 C1-6 烷基，(7) 被羟基或氰基取代的 C2-6 烷基，(8) C2-6 烯基，或 (9) 式-L1-L2-L3，R2 代表氢原子或保护基团；R3 代表氢原子、卤素原子、氰基、氨基、C1-4 烷基或卤代 C1-4 烷基。
• US7074801B1
  申请人：——

  公开号：US7074801B1

  公开（公告）日：2006-07-11